---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115303"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:23:29.289574+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q3 net loss of $33.2M, cash $583M; key readouts expected in Q4 2024 and Q1 2025

## Summary
- Net loss of $33.2M ($0.54 per share) vs $34.1M loss in prior-year Q3.
- Cash, equivalents and marketable securities $583.3M as of Sep 30, up from $341.6M at Dec 31, 2023.
- License & collaboration revenue $4.7M from Takeda deal; $263.8M for nine months includes $255M upfront.
- Top line results expected: JNJ-2113 Phase 3 psoriasis (ICONIC-LEAD/TOTAL) in Q4 2024; Phase 2b UC (ANTHEM) and rusfertide Phase 3 (VERIFY) in Q1 2025.
- Anticipates nomination of oral IL-17 development candidate in Q4 2024; hepcidin and obesity candidates in 2025.

## SEC filing metadata
- accession: 0001104659-24-115303
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465924115303/0001104659-24-115303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465924115303/tm2427679d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115303
- JSON: https://secwatch.observer/filing/0001104659-24-115303.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.